185 related articles for article (PubMed ID: 19266138)
1. Comparative gastrointestinal safety of weekly oral bisphosphonates.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Levin R; Solomon DH
Osteoporos Int; 2009 Oct; 20(10):1735-47. PubMed ID: 19266138
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
3. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
[TBL] [Abstract][Full Text] [Related]
4. Differences in persistence among different weekly oral bisphosphonate medications.
Sheehy O; Kindundu CM; Barbeau M; LeLorier J
Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
6. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
Anastasilakis AD; Goulis DG; Kita M; Avramidis A
Hormones (Athens); 2007; 6(3):233-41. PubMed ID: 17724008
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
[TBL] [Abstract][Full Text] [Related]
8. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD; Möller G
Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
[TBL] [Abstract][Full Text] [Related]
9. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D
J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Kishimoto H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
[No Abstract] [Full Text] [Related]
11. Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Fadda V; Maratea D; Trippoli S; Messori A
J Endocrinol Invest; 2015 Feb; 38(2):189-92. PubMed ID: 25412945
[TBL] [Abstract][Full Text] [Related]
12. [Bisphosphonates for osteoporosis].
Narusawa K; Nakamura T
Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
[No Abstract] [Full Text] [Related]
13. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Adachi JD; Adami S; Miller PD; Olszynski WP; Kendler DL; Silverman SL; Licata AA; Li Z; Gomez-Panzani E
Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
[TBL] [Abstract][Full Text] [Related]
15. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
[TBL] [Abstract][Full Text] [Related]
16. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
17. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
18. Role of alendronate and risedronate in preventing and treating osteoporosis.
Peters ML; Leonard M; Licata AA
Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Nakamura T; Nakano T; Ito M; Hagino H; Hashimoto J; Tobinai M; Mizunuma H;
Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
